Ann: PharmAust Initiates Combination Therapy Evaluations in Dogs, page-80

Lets look at it, these trials have been going on now for nearly 12 months in that time the sp has gone from around .016 to around .007 then back up to .016 and now back down to .009 so the sp has moved up and down.

As for the cap rising the actual number of shares issued was 400m, at the time of the announcement re the issue the sp was trading between .008 - .010 so I think the Management did a fair deal. Money was required to continue the trials so a cap rising was necessary.
Has management made errors yes they have, they have not kept the promise on keeping shareholders up to date on recruitment.

The bad thing is that in the last 12 months the Market Capital has fallen from around $22m to just under $16m. But this is where we are at and it gives paa more upward movement should either or both human and canine trials are successful.

One needs to remember that these trials are being conducted on patients that have failed all other cancer treatments